Xylometazoline
| Evidence Level: L3 | Predicted Indications: 2 |
Table of Contents
Xylometazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
One-Sentence Summary
Xylometazoline is a topical nasal decongestant, originally used for pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, with 0 registered clinical trials and 6 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis, common cold |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L3 |
| US Market Status | Cancelled only (no currently valid licence) |
| Number of NDAs | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, xylometazoline is an imidazoline sympathomimetic that acts as an alpha-adrenergic agonist. It constricts the blood vessels of the nasal mucosa, which reduces swelling and lowers nasal resistance. Pharmacology records list activity at alpha-2 adrenoceptor subtypes (2A, 2B, 2C), although affinity data at the human targets were not available to confirm a primary target.
The original indications, the common cold and pharyngitis, involve upper airway congestion. Nasal cavity disease with obstruction and mucosal swelling shares the same underlying problem, so a vasoconstrictor is mechanistically plausible. The high TxGNN score is a model prediction and does not by itself count as clinical evidence.
A second prediction, acute laryngopharyngitis (score 99.89%), has no supporting trials or literature. Xylometazoline has no demonstrated direct effect on laryngeal or pharyngeal inflammation or infection, so any benefit would be indirect (relief of congestion and postnasal symptoms). This prediction is rated L5 (model prediction only) and Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24158493 | 2013 | RCT (double-blind, placebo-controlled) | JAMA Otolaryngol Head Neck Surg | Intranasal local anaesthetic plus decongestant spray before flexible nasendoscopy in children, compared with placebo |
| 22427029 | 2013 | Randomized blinded study (100 patients) | Eur Arch Otorhinolaryngol | Cotton pledget packing versus topical spray for nasal preparation before endoscopy |
| 24023995 | 2013 | Clinical study | Korean J Anesthesiol | Xylometazoline spray compared with epinephrine gauze packing for expanding the nasal cavity before nasotracheal intubation |
| 1281924 | 1992 | Physiological study | Rhinology | Nasal airflow asymmetry in healthy subjects and in acute rhinitis from the common cold, and how xylometazoline affects it |
| 8740084 | 1996 | Double-blind study | Arzneimittel-Forschung | Rhinomanometric comparison of tuaminoheptane plus N-acetyl-cysteine against xylometazoline and placebo in 18 healthy subjects |
| 34783482 | 2021 | Review | Vestn Otorinolaringol | Nasal mucosa in the elderly and treatment approaches for inflammatory diseases of the nasal cavity and paranasal sinuses, including combined decongestant sprays |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not available | Metarivin Soln. 0.1% (Lydia Co., Ltd.) | Liquid | Not available (licence cancelled) |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): hypertension and hypertensive disorder, diabetes mellitus, diabetic ketoacidosis, heart disease, cardiovascular disease, hyperthyroidism, Graves disease and thyrotoxicosis. These are consistent with caution for sympathomimetic agents.
- Pharmacological target interactions: the compiled data list activity at alpha-1D, alpha-2A, alpha-2B and alpha-2C adrenoceptors and at TAAR4P (mouse). No drug-drug interactions with other medicines were recorded.
Please refer to the package insert for full safety information, as label warnings and contraindications were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and the existing literature (mostly procedural nasal preparation and rhinomanometry studies) is consistent with a decongestant effect. However, no clinical trials are registered, the evidence is largely indirect, and the only US licence is cancelled. Label safety data are also missing, which blocks the safety screening step.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap)
- Confirmed mechanism of action data (for example from DrugBank)
- Clarification of which specific nasal cavity disease conditions are targeted, and review of the full texts of the six publications for relevance
- Confirmation of the regulatory pathway, since the current US licence is cancelled
- A cardiovascular, diabetic and thyroid risk assessment for the flagged patient groups
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.